A detailed history of Royal Bank Of Canada transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,699 shares of MCRB stock, worth $3,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,699
Previous 2,287 105.47%
Holding current value
$3,853
Previous $1,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.56 - $1.19 $1,350 - $2,870
2,412 Added 105.47%
4,699 $3,000
Q1 2024

May 15, 2024

SELL
$0.75 - $1.56 $21,491 - $44,701
-28,655 Reduced 92.61%
2,287 $1,000
Q4 2023

Feb 14, 2024

BUY
$0.93 - $2.15 $16,126 - $37,281
17,340 Added 127.48%
30,942 $43,000
Q3 2023

Nov 14, 2023

BUY
$2.33 - $5.07 $14,425 - $31,388
6,191 Added 83.54%
13,602 $32,000
Q2 2023

Aug 14, 2023

BUY
$4.67 - $6.55 $15,256 - $21,398
3,267 Added 78.84%
7,411 $35,000
Q1 2023

May 15, 2023

SELL
$4.95 - $6.09 $37,941 - $46,679
-7,665 Reduced 64.91%
4,144 $23,000
Q4 2022

Feb 14, 2023

BUY
$5.09 - $9.05 $51,877 - $92,237
10,192 Added 630.3%
11,809 $66,000
Q3 2022

Nov 14, 2022

SELL
$3.5 - $7.2 $60,760 - $124,992
-17,360 Reduced 91.48%
1,617 $11,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.62 $10,635 - $30,015
-3,939 Reduced 17.19%
18,977 $65,000
Q1 2022

May 16, 2022

SELL
$6.3 - $8.84 $67,536 - $94,764
-10,720 Reduced 31.87%
22,916 $162,000
Q4 2021

Feb 14, 2022

BUY
$6.02 - $11.43 $166,723 - $316,553
27,695 Added 466.17%
33,636 $280,000
Q3 2021

Nov 15, 2021

BUY
$5.46 - $22.6 $6,420 - $26,577
1,176 Added 24.68%
5,941 $41,000
Q2 2021

Aug 16, 2021

BUY
$18.46 - $24.36 $87,961 - $116,075
4,765 New
4,765 $114,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $102M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.